GREGORY AJEMIAN: Open Payments
NPI 1962407627 · GARDEN CITY, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,306 in 59 payments from 16 companies in 2025. Trend: 2023 $572 · 2024 $1,578 · 2025 $1,306
Food & beverage: $1,306
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 9 | $185 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 8 | $164 |
| AstraZeneca Pharmaceuticals LP | 6 | $155 |
| GlaxoSmithKline, LLC. | 7 | $147 |
| PFIZER INC. | 5 | $123 |
| Astellas Pharma US Inc | 4 | $101 |
| Amgen Inc. | 5 | $92 |
| Bausch Health US, LLC | 4 | $80 |
| Lilly USA, LLC | 3 | $63 |
| Exact Sciences Corporation | 2 | $53 |
Products named: JARDIANCE, TRELEGY ELLIPTA, Veozah, Ozempic, FARXIGA, APLENZIN, PREVNAR 20, AIRSUPRA.
Industry payments across NY — which companies pay providers there.
